OBJECTIVES:
The National Breast and Cervical Cancer Early Detection Program (NB-CCEDP) is the largest organized cancer screening program for low-income, un-insured and under-insured women in the United States. The program's effectiveness in increasing the life expectancy of participating women has never been measured. We estimated the benefits of NBCCEDP-funded cervical cancer screening (Program) in terms of life-years (LYs) saved compared to No Program and No Screening scenarios. METHODS: Based on an existing model developed by Myers et al., we constructed a cervical cancer simulation model by modifying the age and screening schedule of the cohort to reflect screening frequency for NBCCEDP participants from 1991-2007. We estimated screening habits in the absence of the program based on data from the 1990-2005 National Health Interview Survey. We performed Markov cohort analysis for each age in the 18-64 range and calculated an overall weighted average using the age distribution at first NBCCEDP Pap test for screening. Weighted averages were produced for three scenarios -women receiving testing from the NBCCEDP (the Program), women receiving testing from alternative sources in the absence of the program (No Program), and women receiving no testing at all (No Screening We refined a previously-developed decisionanalytic model to estimate the expected value of perfect information (EVPI) and expected value of sample information (EVSI) for two treatment strategies: 1) ERCC1 testing to inform adjuvant chemotherapy decisions, with ERCC1ϩ patients receiving no chemotherapy and ERCC1-patients receiving chemotherapy; 2) standard care, with all patients receiving no chemotherapy. Model parameters and uncertainty ranges were derived from a retrospective analysis of the International Adjuvant Lung Cancer Trial, published literature, and government sources. The affected population was derived from SEER incidence estimates, and examined over a discounted 10-year time horizon. RESULTS: At a willingness-to-pay of $150,000 per quality-adjusted life year, ERCC1 and standard care strategies resulted in average net-benefits of $630,500 and $625,200, respectively. The ERCC1 and standard care strategies produced greater net-benefit in 64% and 36% of 10,000 simulations, respectively. The average net-benefit difference was $14,000 in simulations where the standard care strategy was optimal. With an affected population of 233,825; EVPI was $1.2 billion. Preliminary estimates suggest an EVSI of approximately $20 million at plausible sample sizes. CONCLUSIONS: Considerable value could be realized through additional research to reduce uncertainty about the comparative health outcomes of ERCC1 and standard care strategies. The EVPI of $1.2 billion was driven by the large 10-year affected population, probability that ERCC1 testing is not the optimal strategy, and consequences of selecting the non-optimal strategy. Forthcoming results will enable estimation of the expected net-benefit of sampling, which compares the EVSI of various study designs and sample sizes to the cost of conducting such studies. These findings can assist stakeholders in prioritizing funding for ERCC1 research relative to alternative research investments.
CN4 PALONOSETRON VERSUS OTHER 5-HYDROXYTRYPTAMINE 3 RECEPTOR ANTAGONISTS FOR PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING AMONG MEDICARE PATIENTS WITH CANCER
Craver C 1 , Gayle J 1 , Balu S 2 , Buchner D 2 1 Premier, Inc., Charlotte, NC, USA, 2 Eisai, Inc., Woodcliff Lake, NJ, USA OBJECTIVES: To assess the rate of uncontrolled chemotherapy induced nausea and vomiting (CINV) associated with palonosetron initiation versus other 5-hydroxy tryptamine 3 -receptor antagonists (5-HT 3 -RAs) among Medicare patients with cancer on chemotherapy (CT) treatment in a hospital outpatient setting. METHODS: Medicare patients with a cancer diagnosis initiating CT and anti-emetic prophylaxis with palonosetron (Group 1) and other 5-HT 3 -RAs (Group 2) for the first time (index date) between April 1, 2007 -March 31, 2009 were identified from the Premier Perspective database. Inclusion criteria were no evidence of nausea and vomiting, CT, and antiemetic medication in the 6-month pre-index date period and 36-consecutive months of data submission. A negative binomial distribution generalized linear multivariate regression model estimating the rate of CINV events on CT emetogenicity and cycle matched groups in the follow-up period (first of eight CT cycles or six months postindex date) was developed after adjusting for several demographic and clinical variables. RESULTS: Of 4799 identified patients, 962 initiated palonosetron (Group 1; 20.1%). Group 1 patients were significantly younger [70.4 (SD: 9.3) versus 71.6 (9.0) years; pϽ0.0001], comprised more females [52.9% versus 48.6%; pϽ0.0001], less African Americans [8.7% vs. 11.3%] and more Hispanic patients [6.3% versus 2.5%]; all pϽ0.0001, more highly and moderately emetogenic CT [33.6% versus 20.7% and; 47.3% versus 40.3%, respectively; pϽ0.0001], and more lung and breast [30.9% vs. 24.9% and 12.3% vs. 9.6%, respectively; pϽ0.0001]. In the follow-up period, the regression model predicted a 11.8% decrease in the CINV events per CT cycle for Group 1 patients versus Group 2 patients; pϽ0.05. CONCLUSIONS: In this retrospective hospital outpatient study, after matching for CT emetogenicity and cycle and adjusting for other potential confounders, Medicare patients with cancer initiated on palonosetron were more likely to experience a significantly lower rate of CINV events per CT cycle versus those initiating other 5-HT3-RAs.
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